Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis

Journal of the Neurological Sciences

Volumn 332, Issue 1-2, 2013, Pages 35-40

  Mitosek Szewczyk, Krystyna ^a   Tabarkiewicz, Jacek ^a   Wilczynska, Barbara ^a   Lobejko, Katarzyna ^a   Berbecki, Jerzy ^a   Nastaj, Marcin ^a   Dworzanska, Ewa ^a   Kolodziejczyk, Beata ^a   Stelmasiak, Zbigniew ^a   Rolinski, Jacek ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

B cell; Cladribine; Dendritic cells; Immunosuppresant; Multiple sclerosis; T cell

Indexed keywords

ALPHA INTERFERON; CD123 ANTIGEN; CD19 ANTIGEN; CD1C ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CLADRIBINE;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE SCLEROSIS; MYELOID DENDRITIC CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

B CELL; CLADRIBINE; DENDRITIC CELLS; IMMUNOSUPPRESANT; MULTIPLE SCLEROSIS; T CELL;

ADULT; ANALYSIS OF VARIANCE; ANTIGENS, CD; B-LYMPHOCYTES; CLADRIBINE; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; T-LYMPHOCYTES;

EID: 84881480381     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2013.06.003     Document Type: Article

References (23)

1. B. Nikbin, M.M. Bonab, F. Khosravi, and F. Talebian Role of B cells in pathogenesis of multiple sclerosis Int Rev Neurobiol 79 2007 13 42
2. B.C. Kieseier, H. Wiendl, H.P. Hartung, and O. Stüve The future of multiple sclerosis therapy Pharmacol Res 60 2009 207 211
3. Z. Stelmasiak, J. Solski, J. Nowicki, B. Jakubowska, M. Ryba, and P. Grieb Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study Mult Scler 15 2009 767 770
4. M.E. Duddy, A. Alter, and A. Bar-Or Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 172 2004 3422 3427
5. R. Hohlfeld, M. Kerschensteiner, and E. Meinl Dual role of inflammation in CNS disease Neurology 68 2007 S58 S63
6. J. Banchereau, and R.M. Steinman Dendritic cells and the control of immunity Nature 392 1998 245 252
7. I. Steinman Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system Cell 85 1996 299 302
8. B. Dubois, C. Massacrier, and C. Caux Selective attraction of naïve and memory B cell by dendritic cells J Leukoc Biol 70 2001 633 641
9. G. Penna, M. Vulcano, S. Sozzani, and L. Adorini Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells Hum Immunol 63 2002 1164 1171
10. S. Lindemalm, J. Liliemark, G. Juliusson, R. Larsson, and F. Albertioni Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia Cancer Lett 210 2 2004 171 177
11. J.C. Sipe Cladribine for multiple sclerosis: review and current status Expert Rev Neurother 5 2005 721 727
12. J.B. Johnston Mechanism of action of pentostatin and cladribine in hairy cell leukemia Leuk Lymphoma 52 Suppl. 2 2011 43 45
13. E. Beutler, J.C. Sipe, J.S. Romine, J.A. Koziol, R. McMillan, and J. Zyroff The treatment of chronic progressive multiple sclerosis with cladribine Proc Natl Acad Sci U S A 93 4 1996 1716 1720
14. G.P. Rice, M. Filippi, and G. Comi Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group Neurology 54 5 2000 1145 1155
15. W.I. McDonald, A. Compston, G. Sdan, D. Goodkin, H.P. Hartung, and F.D. Lublin Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis Ann Neurol 5 2001 121 127
16. J.E. Kurtzke Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1983 1444 1452
17. J.A. Brousil, R.J. Roberts, and A.L. Schlein Cladribine: an investigational immunomodulatory agent for multiple sclerosis Ann Pharmacother 40 2006 1814 1821
18. H.P. Hartung, O. Aktas, B. Kieseier, and G.C. Giancarlo Comi Development of oral cladribine for the treatment of multiple sclerosis J Neurol 257 2 2010 163 170
19. T.P. Leist, and R. Weissert Cladribine: mode of action and implications for treatment of multiple sclerosis Clin Neuropharmacol 34 1 2011 28 35
20. P. Bertazzoni, C. Rabascio, F. Gigli, L. Calabrese, D. Radice, and A. Calleri Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients Leuk Lymphoma 51 8 2010 1485 1493
21. T. Robak, R. Kordek, E. Robak, J. Bartkowiak, W. Biernat, and P. Liberski Langerhans cell histiocytosis in a patient with systemic lupus erythematosus: a clonal disease responding to treatment with cladribine, and cyclophosphamide Leuk Lymphoma 43 10 2002 2041 2046
22. K.L. McClain Drug therapy for the treatment of Langerhans cell histiocytosis Expert Opin Pharmacother 6 14 2005 2435 2441
23. E. Gehrie, W. Van der Touw, J.S. Bromberg, and J.C. Ochando Plasmacytoid dendritic cells in tolerance Methods Mol Biol 677 2011 127 147